- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Skin Cancers | Clinical
More Research on Potency, Efficacy of TILs Is Needed in Melanoma
July 07, 2021
According to Inge Marie Svane, MD, PhD, the truth about what drives tumor-infiltrating lymphocyte efficacy is not yet known, and more research is needed.
FDA Expands Label for Pembrolizumab to Include Treatment of Locally Advanced cSCC
July 06, 2021
The FDA has expanded its approval for pembrolizumab monotherapy to include the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
Cemiplimab Therapy Shows Efficacy in Trial of Advanced CSCC
June 25, 2021
During a Targeted Oncology Case-Based Roundtable event, Michael K. Wong, MD, PhD, discussed the case of a 69-year-old patient with cutaneous squamous cell carcinoma.
Novel IO Approaches Are in Development for PD-1/PD-L1–Resistant Merkel Cell Carcinoma
June 23, 2021
Newer immunotherapy approaches continue to be explored to treat patients with relapsed or refractory MCC after PD-1/ PD-L1 inhibition.
Neoadjuvant Is Superior to Adjuvant Immunotherapy in Stage III Melanoma
June 22, 2021
Research has suggested that neoadjuvant immunotherapy combinations are superior to adjuvant immunotherapy for patients with stage III melanoma.
Adjuvant Targeted Therapy Proves Beneficial in Resected Stage III BRAF-Mutant Melanoma
June 21, 2021
Targeted therapy use in melanoma has been extended beyond just metastatic disease to now include adjuvant therapy for patients with resected stage III melanoma.
APG-115 Plus Pembrolizumab Safe With Preliminary Efficacy in Unresectable or Metastatic Melanoma or Advanced Solid Tumors
June 08, 2021
The combination of alrizomadlin and pembrolizumab was well tolerated in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immuno-oncologic drugs treated in a phase 2 study.
Increased Responses to Lifileucel Plus Pembrolizumab Observed in Patients With Advanced Melanoma
June 04, 2021
In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.
Genetic Testing Informs Treatment Decisions in Melanoma
May 14, 2021
Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.
FDA Grants Orphan Drug Designation to Novel TIL Therapy for Advanced-Stage Melanoma
April 27, 2021
The FDA has granted orphan drug designation to ITIL-168 for the treatment of stage IIB to IV melanoma, an investigational, autologous cell therapy derived from tumor-infiltrating lymphocytes.